Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appetite in Adults

NCT07230951 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-10-30
Last updated
2025-11-17

Condition(s) studied

HealthyAdultAppetiteGlycemic ResponseMealtiming

Investigational drug(s) / intervention(s)

Oven-baked Home FriesOven-baked White Russet PotatoOven-baked FriesDeep Fried, Quick Serve FriesOven-baked Cauliflower Veggie TotsNo Side

Oven-baked Home Fries: Oven-baked Home Fries (241 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

Oven-baked White Russet Potato: Oven-baked White Russet Potato (299 g). Test treatments matched for calories (284 kcal)

Oven-baked Fries: Oven-baked Fries (201 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

Deep Fried, Quick Serve Fries: Deep Fried, Quick Serve Fries (108 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

Oven-baked Cauliflower Veggie Tots: Oven-baked Cauliflower Veggie Tots (186 g; Green Giant). Test treatments matched for calories (284 kcal)

No Side: No side control (no caloric contribution).

Study summary

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 18 - 65 years * within the healthy body weight range \[body mass index (BMI) between 18.5 - 24.9 kg/m2\]. Exclusion Criteria: * have a previous diagnosis of diabetes and gastrointestinal, liver or kidney disease; * have had a major medical or surgical event within the past 6 months; * have had any significant weight fluctuation in the past 6-months; * are taking medication that may influence dependent measures; * are or have been on a diet within the past 6 months; * skip breakfast or are unable to consume test treatment food.

Primary outcome measure(s)

  • Glycemic Response (Acute Phase) — Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
    Blood glucose (mmol/L). Blood glucose concentrations will be measured using a Dexcom G7 CGM system.
  • Rest-of-day Blood Glucose — Continuous measurements for 24 hours post-treatment consumption.
    Blood glucose (mmol/L). Rest-of-day blood glucose concentrations will be determined using a Dexcom G7 CGM system.
  • Ad Libitum Food Intake — At 120 minutes post-treatment consumption
    Lunch pizza meal. Food intake will be determined by weighing the meal before and after serving. The net weight of the test meal will be converted to calories.

Trial sites (1)

FacilityCityRegionStatus
Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University Toronto Ontario Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07230951 on ClinicalTrials.gov ↗ ← All trials in Canada